Wieder H - Search Results

1

Variations of clinical SPECT/CT operations: an international survey.

Wieder H, Freudenberg LS, Czernin J, Navar BN, Israel O, Beyer T. Wieder H, et al. Nuklearmedizin. 2012;51(4):154-60. doi: 10.3413/Nukmed-0467-12-01. Epub 2012 Apr 3. Nuklearmedizin. 2012. PMID: 22473174

2

99mTc-DPD SPECT/CT for localisation of inflammatory and chronic osteoarthritis of the foot and ankle. Comparison with planar imaging and SPECT as a clinical adjunct in radiosynovectomy.

Stollfuss JC, Freudenberg LS, Wieder H. Stollfuss JC, et al. Among authors: wieder h. Nuklearmedizin. 2016 Aug 5;55(4):145-50. doi: 10.3413/Nukmed-0774-15-10. Epub 2016 Apr 11. Nuklearmedizin. 2016. PMID: 27064111

3

Clinical use of bone-targeting radiopharmaceuticals with focus on alpha-emitters.

Wieder HA, Lassmann M, Allen-Auerbach MS, Czernin J, Herrmann K. Wieder HA, et al. World J Radiol. 2014 Jul 28;6(7):480-5. doi: 10.4329/wjr.v6.i7.480. World J Radiol. 2014. PMID: 25071888 Free PMC article. Review.

4

18FDG-PET to assess recurrence and long term survival in patients with malignant melanoma.

Wieder HA, Tekin G, Rosenbaum-Krumme S, Klode J, Altenbernd J, Bockisch A, Nagarajah J. Wieder HA, et al. Nuklearmedizin. 2013;52(5):198-203. doi: 10.3413/Nukmed-0584-13-05. Epub 2013 Aug 23. Nuklearmedizin. 2013. PMID: 23969722

5

Splenic sclerosing haemangioma causes false-positive finding at FDG-PET.

Al-Ibraheem A, Buck AK, Dechow T, Ringshausen I, Langer R, Engels HP, Wieder HA, Sciuk J, Schwaiger M, Herrmann K. Al-Ibraheem A, et al. Among authors: wieder ha. Nuklearmedizin. 2010;49(4):N20-1. doi: 10.3413/Nukmed-0294-10-01. Epub 2010 Aug 3. Nuklearmedizin. 2010. PMID: 20683546 No abstract available.

6

FDG PET and CT in locally advanced adenocarcinomas of the distal oesophagus. Clinical relevance of a discordant PET finding.

Stahl A, Stollfuss J, Ott K, Wieder H, Fink U, Schwaiger M, Weber WA. Stahl A, et al. Among authors: wieder h. Nuklearmedizin. 2005;44(6):249-55; quiz N55-6. Nuklearmedizin. 2005. PMID: 16400385

7

Visualisation of metastatic oesophageal and gastric cancer and prediction of clinical response to palliative chemotherapy using 18FDG PET.

Lorenzen S, Herrmann K, Weber WA, Wieder H, Hennig M, Ott K, Bredenkamp R, Peschel C, Schwaiger M, Lordick F. Lorenzen S, et al. Among authors: wieder h. Nuklearmedizin. 2007;46(6):263-70. doi: 10.3413/nukmed-0074. Nuklearmedizin. 2007. PMID: 18084682

8

Imaging of proliferation in hepatocellular carcinoma with the in vivo marker 18F-fluorothymidine.

Eckel F, Herrmann K, Schmidt S, Hillerer C, Wieder HA, Krause BJ, Schuster T, Langer R, Wester HJ, Schmid RM, Schwaiger M, Buck AK. Eckel F, et al. J Nucl Med. 2009 Sep;50(9):1441-7. doi: 10.2967/jnumed.109.065896. Epub 2009 Aug 18. J Nucl Med. 2009. PMID: 19690030 Free article.

9

18F-FDG PET and 18F-FDG PET/CT for assessing response to therapy in esophageal cancer.

Krause BJ, Herrmann K, Wieder H, zum Büschenfelde CM. Krause BJ, et al. Among authors: wieder h. J Nucl Med. 2009 May;50 Suppl 1:89S-96S. doi: 10.2967/jnumed.108.057232. Epub 2009 Apr 20. J Nucl Med. 2009. PMID: 19380406 Free article. Review.

10

PET tracers in musculoskeletal disease beyond FDG.

Wieder HA, Pomykala KL, Benz MR, Buck AK, Herrmann K. Wieder HA, et al. Semin Musculoskelet Radiol. 2014 Apr;18(2):123-32. doi: 10.1055/s-0034-1371015. Epub 2014 Apr 8. Semin Musculoskelet Radiol. 2014. PMID: 24715445 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

66 results

Search Page